"Phenylurea Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that include the amino-N-phenylamide structure.
| Descriptor ID |
D010671
|
| MeSH Number(s) |
D02.455.426.559.389.703 D02.948.681
|
| Concept/Terms |
Phenylurea Compounds- Phenylurea Compounds
- Compounds, Phenylurea
- Phenylurea Derivatives
- Derivatives, Phenylurea
- Phenylcarbamides
|
Below are MeSH descriptors whose meaning is more general than "Phenylurea Compounds".
Below are MeSH descriptors whose meaning is more specific than "Phenylurea Compounds".
This graph shows the total number of publications written about "Phenylurea Compounds" by people in this website by year, and whether "Phenylurea Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 5 | 5 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 4 | 4 |
| 2009 | 0 | 7 | 7 |
| 2010 | 0 | 6 | 6 |
| 2011 | 1 | 5 | 6 |
| 2012 | 3 | 1 | 4 |
| 2013 | 1 | 1 | 2 |
| 2014 | 4 | 0 | 4 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2018 | 3 | 1 | 4 |
| 2019 | 0 | 2 | 2 |
| 2021 | 2 | 1 | 3 |
| 2022 | 0 | 2 | 2 |
| 2023 | 1 | 2 | 3 |
| 2024 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phenylurea Compounds" by people in Profiles.
-
A plain language summary describing changes in pain associated with uterine fibroids among women receiving relugolix combination therapy. Pain Manag. 2024 Sep; 14(9):469-476.
-
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. J Clin Oncol. 2024 Aug 20; 42(24):2918-2927.
-
Quality of life improvements in women with uterine fibroids treated with relugolix combination therapy during the LIBERTY long-term extension study: A descriptive subgroup analysis in women with anemia at baseline. Int J Gynaecol Obstet. 2024 May; 165(2):431-441.
-
Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2024 Apr; 8:e2300527.
-
Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study. Am J Obstet Gynecol. 2024 02; 230(2):237.e1-237.e11.
-
A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies. Pain Manag. 2023 Apr; 13(4):205-211.
-
EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma. Gastroenterology. 2023 05; 164(6):1006-1008.e3.
-
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials. Obstet Gynecol. 2022 06 01; 139(6):1070-1081.
-
An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Opin Pharmacother. 2022 Mar; 23(4):421-429.
-
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol. 2021 07; 22(7):946-958.